Drug trial for debilitating muscle disease halted after enrolling just six patients

NCT ID NCT05132569

Terminated Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

Summary

This study tested whether an oral drug called tolebrutinib could help control symptoms in adults with moderate-to-severe generalized myasthenia gravis, a disease that causes severe muscle weakness. Participants took either the drug or a placebo pill for 26 weeks while continuing their standard treatments, with the goal of seeing if the drug improved their ability to perform daily activities. The trial was a large Phase 3 study but was terminated after enrolling only six people, so no conclusions about the drug's effectiveness could be reached.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Georgetown University-Site Number:8400008

Washington D.C., District of Columbia, 20007, United States
Harvard Medical School - Brigham and Women's Hospital-Site Number:8400004

Boston, Massachusetts, 02115, United States
Investigational Site Number :1240003

London, Ontario, N6A 5A5, Canada
Investigational Site Number :1240004

Edmonton, Alberta, T6G 2B7, Canada
Investigational Site Number :1560001

Shanghai, 200040, China
Investigational Site Number :1560002

Wuhan, 430030, China
Investigational Site Number :1560003

Chengdu, 610041, China
Investigational Site Number :3480001

Szeged, 6725, Hungary
Investigational Site Number :3480002

Pécs, 7623, Hungary
Investigational Site Number :3800001

Milan, 20132, Italy
Investigational Site Number :3800002

Milan, Lombardy, 20133, Italy
Investigational Site Number :3800003

Roma, 00168, Italy
Investigational Site Number :3800004

Naples, 80131, Italy
Investigational Site Number :3920002

Sagamihara-shi, Kanagawa, 252-0392, Japan
Investigational Site Number :6160001

Zabrze, 41-800, Poland
Investigational Site Number :7240003

L'Hospitalet de Llobregat, Catalunya [Cataluña], 08907, Spain
Investigational Site Number :7240005

Madrid, Madrid, Comunidad de, 28046, Spain
Investigational Site Number :8260001

Liverpool, L9 7LJ, United Kingdom
Investigational Site Number :8260002

Exeter, Devon, EX2 5DW, United Kingdom
Neurology Center of San Antonio, PA-Site Number:8400009

San Antonio, Texas, 00000, United States
SFM Clinical Research, LLC-Site Number:8400006

Boca Raton, Florida, 33487, United States
University of South Florida Health- Morsani Center for Advanced Healthcare-Site Number:8400001

Tampa, Florida, 33612-6601, United States

Conditions

Explore the condition pages connected to this study.

MYASTHENIA GRAVIS